Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

ClinicalTrials.gov ID: NCT06128551

Public ClinicalTrials.gov record NCT06128551. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 10, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Patients With Advanced KRAS G12C-Mutated Solid Tumors

Study identification

NCT ID: NCT06128551
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Revolution Medicines, Inc.; Industry
Enrollment: 534 participants

Conditions and interventions

Conditions

Interventions

Daraxonrasib Drug
Elironrasib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 13, 2023
Primary completion: Nov 30, 2028
Completion: May 31, 2029
Last update posted: Apr 22, 2026

2023 – 2029

United States locations

U.S. sites: 21
U.S. states: 10
U.S. cities: 18

Facility	City	State	ZIP	Site status
City of Hope	Duarte	California	91010	Withdrawn
UC IRVINE Health	Orange	California	92868	Recruiting
UC Davis Comprehensive Cancer Center	Sacramento	California	95817	Recruiting
Stanford Cancer Institute	Stanford	California	94305	Recruiting
University of Colorado Cancer Center	Aurora	Colorado	80045	Recruiting
Florida Cancer Specialists	Sarasota	Florida	34232	Recruiting
Moffitt Cancer Center and Research Institute	Tampa	Florida	33612	Recruiting
Dana Farber Cancer Institute	Boston	Massachusetts	02215	Recruiting
Henry Ford Cancer	Detroit	Michigan	48202	Withdrawn
START Midwest	Grand Rapids	Michigan	49546	Recruiting
Columbia University	New York	New York	10032	Recruiting
NYU Langone Health	New York	New York	10032	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
University of Oklahoma	Oklahoma City	Oklahoma	73104	Recruiting
Sarah Cannon Research Institue	Nashville	Tennessee	37203	Recruiting
Mary Crowley Cancer Research	Dallas	Texas	75230	Completed
MD Anderson	Houston	Texas	77030	Recruiting
NEXT Dallas	Irving	Texas	75039	Recruiting
NEXT Oncology San Antonio	San Antonio	Texas	78229	Recruiting
START Texas	San Antonio	Texas	78229	Recruiting
NEXT Oncology Virginia	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06128551, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 22, 2026 · Synced May 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06128551 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →